XGN vs MYGN

For growth investors, Exagen Inc.

(XGN) is the stronger pick with 19. 7% revenue growth year-over-year, versus -1. 6% for Myriad Genetics, Inc. (MYGN). Analysts rate Myriad Genetics, Inc. (MYGN) a "Hold" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Exagen Inc.

(XGN) delivered a total return of -80. 8%, compared to -85. 5% for Myriad Genetics, Inc. (MYGN). Over 10 years, the gap is even starker: XGN returned -84. 2% versus MYGN's -88. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Exagen Inc.

(XGN) is the lower-risk stock at 1. 37β versus Myriad Genetics, Inc. 's 1. 91β — meaning MYGN is approximately 39% more volatile than XGN relative to the S&P 500. On balance sheet safety, Exagen Inc. (XGN) carries a lower debt/equity ratio of 31% versus 57% for Myriad Genetics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Exagen Inc.

(XGN) is pulling ahead at 19. 7% versus -1. 6% for Myriad Genetics, Inc. (MYGN). On earnings-per-share growth, the picture is similar: Exagen Inc. grew EPS -12. 0% year-over-year, compared to -180. 9% for Myriad Genetics, Inc.. Over a 3-year CAGR, XGN leads at 13. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Exagen Inc.

(XGN) is the more profitable company, earning -30. 0% net margin versus -44. 4% for Myriad Genetics, Inc. — meaning it keeps -30. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MYGN leads at -8. 2% versus -21. 1% for XGN. At the gross margin level — before operating expenses — MYGN leads at 69. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Exagen Inc.

(XGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Myriad Genetics, Inc. (MYGN) carries a higher beta of 1. 91 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XGN: -84. 2%, MYGN: -88. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XGN is a small-cap high-growth stock; MYGN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.